Skip to main content
Clinical Trials/IRCT201305296302N5
IRCT201305296302N5
Completed
Phase 3

A comparative study for efficacy and safety between Zitux (Rituximab manufactured by AryoGen) and Mabthera on patients with chronic lymphocytic leukemia (CLL)

AryoGen Biopharma company0 sites78 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
chronic lymphocytic lukemia.
Sponsor
AryoGen Biopharma company
Enrollment
78
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • inclusion criteria: patient with chronic lymphocytic leukemia according to national cancer institute diagnostic criteria for CLL who hasn't been treated already or is new case of CLL or relapsed/refractory CLL with indication for treatment; Age between 18 to 75; Binet stage disease B,C; ECOG performance status: 0 to 1; CD20 positive; patient has indication for treatment in the beginning of study; written informed consent form. exclusion criteria: Bil\>2 mg/dl; Cr\> 2 mg/dl; Alk\-p\> 2 times of upper limit normal; Trans aminase \> 2 times of upper limit normal; Coexistence of serious active infection or underlying disorder( Hepatitis B,C, HIV positive, cardiopulmonary disease, recent MI, uncontrolled diabetes or HTN, seizure); HBSAg or HBCAb positive; other cancer treatments in the last 5 years; severe autoimmune hemolytic anemia, pregnancy or breast feeding
  • exclusion criteria: Bil\>2 mg/dl; Cr\> 2 mg/dl; Alk\-p\> 2 times of upper limit normal; Trans aminase \> 2 times of upper limit normal; Coexistence of serious active infection or underlying disorder( Hepatitis B,C, HIV positive, cardiopulmonary disease, recent MI, uncontrolled diabetes or HTN, seizure); HBSAg or HBCAb positive; other cancer treatments in the last 5 years; severe autoimmune hemolytic anemia, pregnancy or breast feeding

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials